The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a Phase 2 trial of the investigational agent deucravacitinib as a possible treatment for systemic lupus erythematosus (SLE). Data showed that a significantly higher percentage of patients treated with the study drug met the required reduction of symptoms as evaluated by the SLE Responder Index-4 (SRI-4), a composite measurement of disease activity.
Deucravacitinib is a potential first-in-class inhibitor of Tyrosine kinase 2 (TYK2), which regulates Type I interferons (molecules in the immune system that contribute to tissue damage and lupus symptoms.
The full press release is available on the Lupus Therapeutics website.
